Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Onradivir (ZSP1273) Tablets vs Granules in Healthy Participants
NCT06164431Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anlatrelvir in Influenza A (IAV) (2 arms), sponsored by Raynovent Biotech. Primary endpoints: Maximum observed plasma concentration, Area under the concentration-time curve from time zero to infinity and 1 more. Started Nov 2023; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT06164431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164431.